Monday’s Highlights at Noon: ImmunoCellular Therapeutics (IMUC), Vivus (VVUS), Terra Tech Corp (TRTC), Rexahn Pharma (RNN), Renesola (SOL)

By Carrie Williams

So far Monday, January 14, NASDAQ is up 0.38% and the S&P is up 1.25%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; ImmunoCellular Therapeutics (IMUCResearch Report), Vivus (VVUSResearch Report), Terra Tech Corp (TRTCResearch Report), Rexahn Pharma (RNNResearch Report) and Renesola (SOLResearch Report).

ImmunoCellular Therapeutics is up 22.98% in midday trading to $0.02. Shares opened today at $0.02. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Vivus is up 20.54% in midday trading to $3.99. Shares opened today at $3.31. The company has a 52-week low of $2.15 and a 52-week high of $0.00. Over the last 3 months, the insider sentiment on Vivus has been positive based on 35 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.

Terra Tech Corp is down -20.18% in midday trading to $0.91. Shares opened today at $1.14. The company has a 52-week low of $0.46 and a 52-week high of $0.00. In the last 30 days, insiders purchased $143.8K worth of TRTC shares. Over the last 3 months, the insider sentiment on Terra Tech Corp has been positive based on 23 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Rexahn Pharma is up 15.79% in midday trading to $1.27. Shares opened today at $1.10. The company has a 52-week low of $0.85 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $13.50, marking a 1127.27% potential upside from current levels. In a report issued on December 6, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on RNN, with a price target of $17, which represents a potential upside of 1445% from where the stock is currently trading.

Renesola is up 10.34% in midday trading to $1.60. Shares opened today at $1.45. The company has a 52-week low of $1.15 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.75, marking a 20.69% potential upside from current levels. In a report issued on November 19, Roth Capital analyst Justin Clare reiterated a Hold rating on SOL, with a price target of $1.75, which represents a potential upside of 21% from where the stock is currently trading.

Trending Stocks Based on Insider Activity >>